{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Cutaneous+Melanoma&page=2",
    "query": {
      "condition": "Unresectable Cutaneous Melanoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Cutaneous+Melanoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T21:21:55.399Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01605162",
      "title": "Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wild Type BRAF Stage IV Melanoma",
        "Unresectable Stage III Melanoma"
      ],
      "interventions": [
        {
          "name": "TMZ",
          "type": "DRUG"
        },
        {
          "name": "E7016",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2012-05",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2016-07-28",
      "last_synced_at": "2026-06-10T21:21:55.399Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01605162"
    },
    {
      "nct_id": "NCT04375527",
      "title": "Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC V8",
        "Clinical Stage IV Cutaneous Melanoma AJCC V8",
        "Locally Advanced Cutaneous Melanoma",
        "Metastatic Cutaneous Melanoma",
        "Pathologic Stage III Cutaneous Melanoma AJCC V8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC V8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC V8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC V8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC V8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC V8",
        "Unresectable Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2020-12-03",
      "completion_date": "2024-11-22",
      "has_results": false,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-06-10T21:21:55.399Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04375527"
    },
    {
      "nct_id": "NCT02120222",
      "title": "Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Melanoma"
      ],
      "interventions": [
        {
          "name": "selinexor",
          "type": "DRUG"
        },
        {
          "name": "Correlative studies",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kari Kendra",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2014-08-22",
      "completion_date": "2018-04-08",
      "has_results": false,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-06-10T21:21:55.399Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02120222"
    },
    {
      "nct_id": "NCT04940299",
      "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Locally Advanced Bladder Carcinoma",
        "Locally Advanced Bladder Urothelial Carcinoma",
        "Locally Advanced Lung Non-Small Cell Carcinoma",
        "Locally Advanced Renal Pelvis Carcinoma",
        "Locally Advanced Renal Pelvis Urothelial Carcinoma",
        "Locally Advanced Ureter Urothelial Carcinoma",
        "Locally Advanced Urethral Urothelial Carcinoma",
        "Malignant Solid Neoplasm",
        "Metastatic Bladder Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Melanoma",
        "Metastatic Renal Pelvis Urothelial Carcinoma",
        "Metastatic Ureter Urothelial Carcinoma",
        "Metastatic Urethral Carcinoma",
        "Metastatic Urethral Urothelial Carcinoma",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Bladder Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v6",
        "Stage IV Renal Pelvis Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2021-09-23",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-06-10T21:21:55.399Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04940299"
    },
    {
      "nct_id": "NCT04913285",
      "title": "A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Non-small Cell Lung Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "KIN-2787",
          "type": "DRUG"
        },
        {
          "name": "KIN-2787 and binimetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pierre Fabre Medicament",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2021-08-04",
      "completion_date": "2029-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-06-10T21:21:55.399Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04913285"
    },
    {
      "nct_id": "NCT00121225",
      "title": "Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ciliary Body and Choroid Melanoma, Medium/Large Size",
        "Extraocular Extension Melanoma",
        "Iris Melanoma",
        "Uveal Melanoma",
        "Recurrent Intraocular Melanoma",
        "Recurrent Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2005-09",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2019-01-29",
      "last_synced_at": "2026-06-10T21:21:55.399Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Rockledge, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Rockledge",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00121225"
    },
    {
      "nct_id": "NCT02452281",
      "title": "Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "HSPPC-96",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rabih Said",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-12",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2016-01-25",
      "last_synced_at": "2026-06-10T21:21:55.399Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02452281"
    },
    {
      "nct_id": "NCT02141542",
      "title": "Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "MEDI3617",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "F. Stephen Hodi, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2014-05",
      "completion_date": "2020-09-23",
      "has_results": false,
      "last_update_posted_date": "2023-05-01",
      "last_synced_at": "2026-06-10T21:21:55.399Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02141542"
    },
    {
      "nct_id": "NCT03712358",
      "title": "PVSRIPO for Patients With Unresectable Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "PVSRIPO",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Istari Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-11-26",
      "completion_date": "2021-03-23",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-06-10T21:21:55.399Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03712358"
    },
    {
      "nct_id": "NCT01433991",
      "title": "A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Golvatinib",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-10-13",
      "completion_date": "2017-03-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-06-10T21:21:55.399Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01433991"
    }
  ]
}